Chronic myelogenous leukemia staging
|
Chronic myelogenous leukemia Microchapters |
|
Differentiating Chronic myelogenous leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic myelogenous leukemia staging On the Web |
|
American Roentgen Ray Society Images of Chronic myelogenous leukemia staging |
|
Directions to Hospitals Treating Chronic myelogenous leukemia |
|
Risk calculators and risk factors for Chronic myelogenous leukemia staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Chronic myelogenous leukemia may be classified according to the clinical characteristics and laboratory findings into five subtypes: chronic phase, accelerated phase, blast crisis, relapsed or recurrent CML and refractory disease. The earliest phase is the chronic phase and generally has the best response to treatment. The accelerated phase is a transitional phase and blastic phase is a aggressive phase that becomes life-threatening. Relapsed CML means that the number of blast cells in the blood and bone marrow increase after remission and finally, refractory disease means the leukemia did not respond to treatment.
Classification
Chronic myelogenous leukemia is often divided into five phases based on clinical characteristics and laboratory findings.[1]
- Chronic. The chronic phase is the earliest phase and generally has the best response to treatment.
- Accelerated. The accelerated phase is a transitional phase when the disease becomes more aggressive.
- Blastic. Blastic phase is a severe, aggressive phase that becomes life-threatening.
- Relapsed CML. Relapsed, or recurrent CML means that the number of blast cells in the blood and bone marrow increase after treatment.
- Refractory disease. It means the leukemia did not respond to treatment.
References
- ↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/staging/?region=ab